The proposed bill establishes a new chapter in Title 69 RCW focused on promoting the use of alternative, nonanimal test methods in drug development. The legislature recognizes that a significant percentage of drugs tested on animals fail to meet safety and efficacy standards for human use and that alternative methods can yield more relevant results while reducing development time and costs. The bill mandates that no animal testing facility, contract testing facility, or manufacturer may use animal test methods in drug development when an alternative is available, thereby prioritizing consumer safety and efficiency in drug development.

Additionally, the bill outlines definitions for key terms such as "alternative test method," "animal testing facility," and "drug development process." It emphasizes that violations of this chapter are considered unfair or deceptive acts under the consumer protection act, thereby reinforcing the public interest in these practices. However, the bill also clarifies that it does not apply when an animal test method is mandated by federal regulatory authorities. Overall, the legislation aims to align state practices with public sentiment and federal support for nonanimal testing methods.